Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Natural killer (NK) cells play a key role in innate immune responses and are an important component of anti-cancer defenses. This study aimed to investigate the clinicopathological characteristics of NK cell activity (NKA) among various hematological malignancies at diagnosis and to evaluate their clinical value as a monitoring marker. Methods: A total of 111 patients that were newly diagnosed with hematological malignancies were recruited, comprising 18 acute myeloid leukemia (AML), 31 multiple myeloma (MM), and 62 lymphoma. Twenty-three normal control subjects from our health examination center were recruited. NKA was measured using a commercially available enzyme-linked immunosorbent assay kit, which measures interferon-gamma secreted by ex vivo-stimulated NK cells in whole blood. Results: The 111 patients had a median NKA of 202.80 pg/mL (range 40–2,000). NKA was significantly decreased in patients with AML (median 47.05 pg/mL, 40–2,000, P <0.0001), MM (275.00, 40–2,000, P <0.0001), and lymphoma (289.49, 40–2,000, P <0.0001) compared with that in normal controls (1,891, 412–2,000). There was a difference in NKA between AML and lymphoma (P =0.0499). Serial changes in NKA correlated with disease progression. NKA did not correlate with the NK cell count in any group of hematological malignancies. Conclusions: The measurement of NKA could be useful to evaluate the immunological status in hematological malignancies at diagnosis and during follow-up.
Abstract
Background: Natural killer (NK) cells play a key role in innate immune responses and are an important component of anti-cancer defenses. This study aimed to investigate the clinicopathological characteristics of NK cell activity (NKA) among various hematological malignancies at diagnosis and to evaluate their clinical value as a monitoring marker. Methods: A total of 111 patients that were newly diagnosed with hematological malignancies were recruited, comprising 18 acute myeloid leukemia (AML), 31 multiple myeloma (MM), and 62 lymphoma. Twenty-three normal control subjects from our health examination center were recruited. NKA was measured using a commercially available enzyme-linked immunosorbent assay kit, which measures interferon-gamma secreted by ex vivo-stimulated NK cells in whole blood. Results: The 111 patients had a median NKA of 202.80 pg/mL (range 40–2,000). NKA was significantly decreased in patients with AML (median 47.05 pg/mL, 40–2,000, P <0.0001), MM (275.00, 40–2,000, P <0.0001), and lymphoma (289.49, 40–2,000, P <0.0001) compared with that in normal controls (1,891, 412–2,000). There was a difference in NKA between AML and lymphoma (P =0.0499). Serial changes in NKA correlated with disease progression. NKA did not correlate with the NK cell count in any group of hematological malignancies. Conclusions: The measurement of NKA could be useful to evaluate the immunological status in hematological malignancies at diagnosis and during follow-up.
참고문헌 (29)
- Campbell KS, "Natural killer cell biology: an update and future directions", J Allergy Clin Immunol, 132, pp.536~544 (2013)[DOI]
- Benjamin JE, "Biology and clinical effects of natural killer cells in allogeneic transplantation", Curr Opin Oncol, 22, pp.130~137 (2010)[DOI]
- Hazeldine J, "The impact of ageing on natural killer cell function and potential consequences for health in older adults", Ageing Res Rev, 12, pp.1069~1078 (2013)[DOI]
- Huang H, "The immune system in aging: roles of cytokines, T cells and NK cells", Front Biosci, 10, pp.192~215 (2005)[DOI]
- Imai K, "Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population", Lancet, 356, pp.1795~1799 (2000)[DOI]
- Schleypen JS, "Renal cell carcinoma-inltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specic HLA class I allotypes", Int J Cancer, 106, pp.905~912 (2003)[DOI]
- Mandal A, "Natural killer cells: in health and disease", Hematol Oncol Stem Cell Ther, 8, pp.47~55 (2015)[DOI]
- Ruggeri L, "Natural killer cell alloreactivity in allogeneic hematopoietic transplantation", Curr Opin Oncol, 19, pp.142~147 (2007)[DOI]
- Baier C, "Natural killer cells modulation in hematological malignancies", Front Immunol, 4, pp.459~ (2013)
- Viel S, "Monitoring NK cell activity in patients with hematological malignancies", Oncoimmunology, 2, pp.e26011~ (2013)[DOI]
- Miller JS, "Therapeutic applications: natural killer cells in the clinic", Hematology Am Soc Hematol Educ Program, 2013, pp.247~253 (2013)
- Rezvani K, "The application of natural killer cell immunotherapy for the treatment of cancer", Front Immunol, 6, pp.578~ (2015)
- Lee SB, "A high-throughput assay of NK cell activity in whole blood and its clinical application", Biochem Biophys Res Commun, 445, pp.584~590 (2014)[DOI]
- Koo KC, "Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer", PLoS One, 8, pp.e78049~ (2013)[DOI]
- Cheson BD, "Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia", J Clin Oncol, 21, pp.4642~4649 (2003)[DOI]
- Palumbo A, "International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation", J Clin Oncol, 32, pp.587~600 (2014)[DOI]
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)[DOI]
- Mukaka MM, "Statistics corner: a guide to appropriate use of correlation coefcient in medical research", Malawi Med J, 24, pp.69~71 (2012)
- Whiteside TL, "Natural killer cells and natural killer cell activity in chronic fatigue syndrome", Am J Med, 105, pp.27S~34S (1998)
- Farnault L, "Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications", Clin Dev Immunol, 2012, pp.421702~ (2012)
- Stringaris K, "Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia", Haematologica, 99, pp.836~847 (2014)[DOI]
- Parry HM, "NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma", Oncotarget, 7, pp.68513~68526 (2016)
- Konjevic G, "The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease", Br J Haematol, 104, pp.144~151 (1999)[DOI]
- Brenner CD, "Requirements for control of B-cell lymphoma by NK cells", Eur J Immunol, 40, pp.494~504 (2010)[DOI]
- Khaznadar Z, "Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion", J Immunol, 195, pp.2580~2590 (2015)[DOI]
- Jurisic V, "Clinical stagedepending decrease of NK cell activity in multiple myeloma patients", Med Oncol, 24, pp.312~317 (2007)[DOI]
- Mitsiades CS, "Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma", Crit Rev Oncol Hematol, 88(Suppl 1), pp.S5~S13 (2013)[DOI]
- Dunbar EM, "The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease", Haematologica, 93, pp.1852~1858 (2008)[DOI]
- Jacobs B, "NK cell subgroups, phenotype, and functions after autologous stem cell transplantation", Front Immunol, 6, pp.583~ (2015)